1119512-39-8

Basic information

• Product Name: 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester
• Synonyms: 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester;3-Aza-bicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl es;3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid, 3-(1,1-diMethylethyl) ester;3-(tert-Butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid;3-[(2-methylpropan-2-yl)oxycarbonyl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid
• CAS NO: 1119512-39-8
• Molecular Formula: C11H17NO4
• Molecular Weight: 227
• Mol File: 1119512-39-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 356℃
• Flash Point: 169℃
• Appearance: /
• Density: 1.276
• PKA: 4.56±0.20(Predicted)
• CAS DataBase Reference: 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester(1119512-39-8)
• EPA Substance Registry System: 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester(1119512-39-8)

Safety Data

• Hazardous Substances Data: 1119512-39-8(Hazardous Substances Data)

Usage

General Description

3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester is a chemical compound with the molecular formula C12H19NO4. It is a derivative of the natural compound rigidin, and it has potential applications in the field of medicinal chemistry. The compound is a tert-butyl ester, and it contains a bicyclic ring structure with two carboxylic acid functional groups. 3-Azabicyclo[3.1.0]hexane-3,6-dicarboxylic acid 3-tert-butyl ester may have potential pharmaceutical properties, and it could be used as a building block for the synthesis of other biologically active molecules. However, further research is necessary to fully understand its properties and potential applications.

Upstream product

• 827599-20-2 3-tert-butyl 6-ethyl (1R*,5S*,6S*)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 419572-18-2 (1R,5S,6r)-tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 187681-87-4 (1R,5S,6s)-2,4-dioxo-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid 
• 1366657-90-0 (1R,5S,6r)-3-benzyl-2,4-dioxo-3-azabicyclo[3.1.0]hexane-6-carboxylic acid 
• 134575-05-6 ethyl 5-benzyl-4,6-dioxo-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrazole-3-carboxylate 
• 705-35-1 trans,meso-1,2,3-cyclopropanetricarboxylic acid 
• 13949-99-0 trans,meso-cyclopropanetricarboxylic acid triethyl ester 
• 134575-13-6 (1α,5α,6α)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane 
• 134575-07-8 (1α,5α,6α)-6-hydroxymethyl-3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 134575-37-4 3-(tert-butyl) 6-ethyl (1R,5S,6r)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 146726-13-8 3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylic acid ethyl ester 

Downstream Products

• 1564262-59-4 C₁₆H₁₈N₂O₂S 
• 1564262-60-7 C₁₆H₁₇FN₂O₂S 
• 1564262-31-2 C₁₉H₂₄Cl₂N₂O₃S 
• 1564262-32-3 C₂₀H₂₆Cl₂N₂O₃S 
• 1564262-33-4 C₂₀H₂₆Cl₂N₂O₃S 
• 1564262-34-5 C₂₁H₂₆Cl₂N₂O₃S 
• 1564262-35-6 C₂₁H₂₈Cl₂N₂O₃S 
• 1564262-36-7 C₂₁H₂₈Cl₂N₂O₃S 
• 1564262-37-8 C₂₂H₂₃Cl₂N₃O₃S 
• 1564262-38-9 C₂₂H₂₃Cl₂N₃O₃S 
• 1564262-39-0 C₂₃H₂₄Cl₂N₂O₃S 
• 1564262-40-3 C₂₃H₂₃Cl₂FN₂O₃S 
• 871239-62-2 tert-butyl (1R,5S,6r)-6-cyano-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1564262-44-7 C₂₁H₂₄Cl₂N₄O₃S 

Relevant articles and documents

Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain

A new series of aryls, including benzo[d]imidazole/isoxazole/pyrazole, conjugated to 3N-substituted-azabicyclo[3.1.0]hexane derivatives were designed and synthesized as inhibitors of T-type calcium channels. Among the synthesized compounds, 3N-R-substituted azabicyclo[3.1.0]hexane carboxamide derivatives containing 5-isobutyl-1-phenyl-pyrazole ring exhibited potent and selective T-channel inhibition and good metabolic stability without CYP450 inhibition. Compounds 10d and 10e contained hydrophobic substituents at the 3N-position and exhibited potent in vitro efficacy, as well as neuropathic pain alleviation in rats.

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS

The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.